# Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

> **NCT02903537** · PHASE1 · UNKNOWN · sponsor: **Fundació Institut Germans Trias i Pujol** · enrollment: 16 (estimated)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Chronic Progressive

## Interventions

- **DRUG:** Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
- **DRUG:** Interferon-beta

## Key facts

- **NCT ID:** NCT02903537
- **Lead sponsor:** Fundació Institut Germans Trias i Pujol
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-06
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903537, "Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02903537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*